ReviewKidney medicine2026
Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept.
Review in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) ranges in heterogeneity and unpredictable course, leading to high morbidity and mortality. For decades, the mainstream treatment protocol for IgAN has been long-term corticosteroids, which is combined with immunosuppression therapy in a subset of patients. Recent studies have demonstrated that side effects related to long-term corticosteroid and immunosuppressive therapy limit patient adherence to long-term treatment and subsequently impair efficacy. Therefore, there is an urgent need for a novel long-term regimen that spares corticosteroid- and immunotherapy-related side effects and prevent the patient from progressing to end-stage renal disease. Because of the lack of consensus on the treatment protocol, research has been conducted to explore pathogenesis-specific treatments for IgAN. In recent years, the BAFF/APRIL axis has been shown to play a principal role in the pathogenesis of IgAN. In this review, we explore the recent clinical trials that specifically target the pathogeneses of IgAN and review the deeper aspects of the current IgAN treatment protocol. Additionally, we review diverse perspectives on drugs that interfere with the BAFF/APRIL axis, particularly telitacicept-a fully human IgG1-Fc soluble fusion protein. Significance Statement: Better understanding of IgA nephropathy has helped researchers to discover new targeted drugs that act on specific pathogenic pathways. These treatments offer a new way to slow or stop kidney damage due to this condition. This review explains the key role of the BAFF/APRIL pathway and critiques the therapeutic role of telitacicept. It also provides a clear, easy-to-follow summary of real-world targeted therapy for doctors, researchers, and the public.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.